BI’s Article search uses Boolean search capabilities. If you are not familiar with these principles, here are some quick tips.
To search specifically for more than one word, put the search term in quotation marks. For example, “workers compensation”. This will limit your search to that combination of words.
To search for a combination of terms, use quotations and the & symbol. For example, “hurricane” & “loss”.
Reprints
An experimental drug from Eisai Co. Ltd. and Biogen Inc. significantly slowed the decline of people with Alzheimer’s disease in a large Phase 3 clinical trial, a surprise finding that could revitalize a research field accustomed to disappointing study results, Healthcare Dive reports. Eisai and Biogen’s lecanemab works by blocking a form of a protein known as amyloid, accumulations of which in the brain have been linked to the characteristic loss of memory, orientation and function in Alzheimer’s.
1. Ford sues BCBS Association alleging price fixing that drove up costs
2. Benefytt Technologies files for bankruptcy after paying fraud settlements
3. More than 60% of retirees would like a do-over on retirement planning: Survey
4. UnitedHealth revises controversial prior authorization plan for colonoscopies
5. Cyber attack on dental insurance plan compromises nearly 9 million individuals